ABSTRACT
The advent of combinatorial chemistry and high throughput screening (HTS) has changed the way that drug discovery is approached in pharmaceutical companies and biotechnology companies worldwide. However, laboratory capabilities have progressed so rapidly that their use has tended to be ad hoc rather than part of a well-defined methodology for drug discovery. Known synthetic routes can produce far more compounds than can be synthesized and screened at reasonable cost. Therefore it is important to apply rational selection criteria to decide which compounds to include in a diverse screening library. This chapter describes the selection of a large diverse screening library of compounds 1 for use in exploratory HTS, based on a clear conceptual view.
